Urotensin II
Human Urotensin II
11 Amino Acids · MW: ~1,334 Da
Amino Acids
11
Molecular Weight
~1,334 Da
Half-life
~minutes
Research Score
4.0
Studies
250
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Urotensin II?
A potent cyclic vasoactive peptide considered one of the strongest endogenous vasoconstrictors. It is studied for vascular reactivity, endothelial signaling, cardiac remodeling, and pulmonary hypertension.
Key Benefits & Mechanisms
vascular signaling research
smooth-muscle receptor targeting
cardiac remodeling models
biomarker exploration
Research Summary
Urotensin II research has clarified the UT receptor pathway in vascular smooth muscle and endothelial biology. Depending on vascular bed and disease state, it can produce marked vasoconstriction and has been investigated in hypertension, heart failure, and pulmonary vascular disease.
Related Peptides
Carperitide
Recombinant human atrial natriuretic peptide (α-hANP)
Recombinant human atrial natriuretic peptide used mainly in acute heart failure and perioperative volume overload. It promotes natriuresis, vasodilation, and suppression of RAAS signaling to lower preload and afterload.
CardiovascularNesiritide
Recombinant human B-type natriuretic peptide (BNP-32)
Synthetic BNP used to counteract fluid overload and elevated cardiac filling pressures. It increases cyclic GMP, causing venous and arterial vasodilation plus natriuresis.
CardiovascularUlaritide
Synthetic human urodilatin
Urodilatin is a renal natriuretic peptide derived from the proANP precursor and studied as an IV heart-failure therapy. It produces strong natriuresis and vasodilation with a relatively rapid onset.
CardiovascularCenderitide
CD-NP chimeric natriuretic peptide
Cenderitide is a designer natriuretic peptide combining features of CNP and dendroaspis natriuretic peptide. It was engineered to provide balanced natriuretic and vasodilatory activity with potential renal-sparing effects.
Cardiovascular